|
rs9554320
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our findings suggest that, although VEGFR1 rs9582036 and rs9554320 are involved in sunitinib therapy outcome, its clinical use as biomarkers for prediction of sunitinib outcome in mRCC patients is limited, due to inconsistent findings when analyzing all existing studies together.
|
27901483 |
2017 |
|
rs9554320
|
|
|
0.030 |
GeneticVariation |
BEFREE |
VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib (<i>n</i> = 3), but not in progression-free survival (PFS).
|
28978162 |
2017 |
|
rs9582036
|
|
|
0.030 |
GeneticVariation |
BEFREE |
VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib (<i>n</i> = 3), but not in progression-free survival (PFS).
|
28978162 |
2017 |
|
rs9582036
|
|
|
0.030 |
GeneticVariation |
BEFREE |
VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
|
27901483 |
2017 |
|
rs9554320
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Ninety-one patients were included.We found that mRCC patients with the CC-variant in rs9582036 in VEGFR1 have a poorer response rate (RR) (0% vs. 46%, p = 0.028), a poorer PFS (10 vs. 18 months, p = 0.033 on univariate and 0.06 on multivariate analysis) and a poorer OS (14 vs. 31 months, p = 0.019 on univariate and 0.008 on multivariate analysis) compared to patients with the AC- and AA-genotypes. mRCC patients with the AA-variant in rs9554320 in VEGFR1 have a poorer PFS (12 vs. 21 months, p = 0.0066 on univariate and 0.005 on multivariate analysis) and a poorer OS (22 vs. 34 months, p = 0.019 on univariate and 0.067 on multivariate analysis) compared to patients with the AC- and CC-genotypes.Interpretation. mRCC patients with the CC-genotype in VEGFR1 SNP rs9582036 have a poorer response rate, PFS and OS when treated with sunitinib.
|
23421954 |
2014 |
|
rs9582036
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Ninety-one patients were included.We found that mRCC patients with the CC-variant in rs9582036 in VEGFR1 have a poorer response rate (RR) (0% vs. 46%, p = 0.028), a poorer PFS (10 vs. 18 months, p = 0.033 on univariate and 0.06 on multivariate analysis) and a poorer OS (14 vs. 31 months, p = 0.019 on univariate and 0.008 on multivariate analysis) compared to patients with the AC- and AA-genotypes. mRCC patients with the AA-variant in rs9554320 in VEGFR1 have a poorer PFS (12 vs. 21 months, p = 0.0066 on univariate and 0.005 on multivariate analysis) and a poorer OS (22 vs. 34 months, p = 0.019 on univariate and 0.067 on multivariate analysis) compared to patients with the AC- and CC-genotypes.Interpretation. mRCC patients with the CC-genotype in VEGFR1 SNP rs9582036 have a poorer response rate, PFS and OS when treated with sunitinib.
|
23421954 |
2014 |
|
rs4796793
|
|
|
0.020 |
GeneticVariation |
BEFREE |
STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
|
26833481 |
2016 |
|
rs4796793
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs4796793 genotype appears to be a novel factor for mTKI-induced HFSR in patients with mRCC.
|
26300443 |
2016 |
|
rs2010963
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, <i>VEGFA</i> rs2010963 was associated with poorer PFS of mRCC (<i>n</i> = 1).
|
28978162 |
2017 |
|
rs34231037
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
|
28430711 |
2017 |
|
rs4646437
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, hypertension is more likely to occur in A-allele carriers of the CYP3A4 rs4646437 variant in our cohort of mRCC patients treated with sunitinib.
|
26810136 |
2017 |
|
rs5275
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It is the first time that association of rs5275 with survival in mRCC patients is described.
|
28117391 |
2017 |
|
rs2071559
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No SNP predicted axitinib outcomes.Although VEGFR2 rs2071559 predicted sorafenib efficacy in patients with mRCC, sensitivity/specificity limitations preclude its use for selecting individual patients for sorafenib treatment.
|
25816720 |
2015 |
|
rs2231142
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among 12 genetic polymorphisms, polymorphism in the ABCG2 421C>A gene may be mostly associated with the risk of sunitinib-related toxicity in mRCC patients.
|
24013576 |
2013 |